AstraZeneca wins FDA approval for key new lung cancer pill

LONDON A new lung cancer pill from AstraZeneca, designed for patients whose disease has worsened after treatment with other therapies, was approved by U.S. regulators on Friday, in a boost for the British drugmaker.

Tagrisso, also known as AZD9291, is one of several cancer medicines AstraZeneca hopes will rebuild its sales following patent losses on older drugs. During its defense against a takeover attempt by Pfizer last year, the firm…

More

You may also like...